NASDAQ:PRAHPRA Health Sciences Stock Price, Forecast & News

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRAH stock has increased by 7.2% and is now trading at $95.05. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for PRA Health Sciences.

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for PRA Health Sciences.

PRA Health Sciences will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PRA Health Sciences Inc (NASDAQ:PRAH) issued its quarterly earnings results on Thursday, April, 30th. The medical research company reported $1.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.01 by $0.04. The medical research company earned $783.71 million during the quarter, compared to the consensus estimate of $749.61 million. PRA Health Sciences had a return on equity of 27.59% and a net margin of 7.66%. PRA Health Sciences's revenue for the quarter was up 8.5% on a year-over-year basis. During the same period last year, the business earned $1.10 earnings per share. View PRA Health Sciences' earnings history.

PRA Health Sciences issued an update on its second quarter earnings guidance on Thursday, April, 30th. The company provided EPS guidance of $0.75-0.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.91. The company issued revenue guidance of $705-740 million, compared to the consensus revenue estimate of $666.91 million.

11 equities research analysts have issued 1 year price targets for PRA Health Sciences' stock. Their forecasts range from $82.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $101.00 in the next twelve months. This suggests a possible upside of 6.3% from the stock's current price. View analysts' price targets for PRA Health Sciences.

News stories about PRAH stock have trended negative this week, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PRA Health Sciences earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about PRA Health Sciences.

PRA Health Sciences saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,770,000 shares, an increase of 35.1% from the May 31st total of 1,310,000 shares. Based on an average daily volume of 504,600 shares, the short-interest ratio is presently 3.5 days. Currently, 2.8% of the shares of the company are sold short. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Applied Materials (AMAT), Veeva Systems (VEEV), Walt Disney (DIS), Paypal (PYPL), Home Depot (HD), Lam Research (LRCX) and UnitedHealth Group (UNH).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $95.05.

PRA Health Sciences has a market capitalization of $6.06 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

The official website for PRA Health Sciences is www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]